GlassScriptPhysician profile
Laura A Shaver
NPI 1891724514
$3,492.75
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $521 · 2020: $1,154 · 2021: $1,601 · 2022: $203 · 2023: $13.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $410.90 | 2019-2021 | |
| Abbvie INC. | $406.08 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $373.56 | 2019-2023 | |
| Novo Nordisk INC | $360.40 | 2019-2022 | |
| Glaxosmithkline, LLC. | $311.57 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $248.92 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $243.42 | 2019-2021 | |
| Amgen INC. | $242.02 | 2020-2021 | |
| Baxter Healthcare | $159.63 | 2019-2020 | |
| Daiichi Sankyo INC. | $79.25 | 2020-2022 | |
| Pfizer INC. | $76.16 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $73.25 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $60.89 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.45 | 2019-2021 | |
| Amarin Pharma, INC. | $56.14 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $48.65 | 2020-2021 | |
| Astellas Pharma US INC | $42.81 | 2020 | |
| Sunovion Pharmaceuticals INC. | $32.09 | 2021 | |
| Csl Behring | $30.66 | 2019 | |
| Zimmer Biomet Holdings, INC. | $28.78 | 2019 | |
| Shire North American Group INC | $16.51 | 2019 | |
| Medtronic USA, INC. | $15.08 | 2019 | |
| Mylan Specialty L.P. | $14.53 | 2020 | |
| Optinose US, INC. | $14.16 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.58 | 2021 | |
| Portola Pharmaceuticals, LLC | $13.33 | 2019 | |
| Allergan, INC. | $12.98 | 2020 | |
| Ironwood Pharmaceuticals, INC | $12.74 | 2019 | |
| Merck Sharp & Dohme LLC | $12.67 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.52 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $12.02 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Shaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.